Brief: Stoke Therapeutics Reports Q3 Financial Results And Provides Business Updates

Stoke Therapeutics

14/11/2022 13:08

Nov 14 (Reuters) - Stoke Therapeutics Inc  STOK.O :
    * STOKE THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS
AND
PROVIDES BUSINESS UPDATES
    * POSITIVE INTERIM DATA FROM ONGOING PHASE 1/2A CLINICAL
STUDIES
OF STK-001 IN CHILDREN AND ADOLESCENTS WITH DRAVET SYNDROME
    * SINGLE AND MULTIPLE DOSES OF STK-001 UP TO 45MG WERE
WELL-TOLERATED
    * QTRLY LOSS PER SHARE $0.66
    * CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES, AND
RESTRICTED
CASH, ANTICIPATED TO FUND OPERATIONS INTO 2025
    * Q3 EARNINGS PER SHARE VIEW $-0.68 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw6tsNsRa 
Further company coverage:  STOK.O 
 ((Reuters.Briefs@thomsonreuters.com;))